Provectus Capital Partners completes first investment of PCP SEE Fund II by partnering with Polyclinic dr Balog and Optics Balog and launching regional ophthalmology healthcare platform
Zagreb, 26 February 2026 – Provectus Capital Partners (“PCP” or “Provectus”) announces the successful closing of the first transaction of its newly raised PCP SEE Fund II with the investment in Polyclinic dr Balog, a leading specialized ophthalmology polyclinic based in Osijek, Croatia.
Founded and led by Dr Slaven Balog, Polyclinic dr Balog is a well-established ophthalmic medical center providing a comprehensive range of diagnostic and surgical services, including advanced cataract, IOL (Intraocular Lens) and ICL (Implantable Collamer Lens) procedures. The clinic is recognized for its experienced clinical team, modern technology and strong reputation for medical excellence and patient care.
Through this partnership, Provectus will support the clinic’s next phase of growth through further investment in capacity, technology and organizational development, while preserving its best-in-class ophthalmic care and patient-focused approach.
At the same time, the transaction marks the launch of a broader regional strategy aimed at establishing an independent ophthalmology healthcare platform in Southeast Europe (SEE). Building on Polyclinic dr Balog, Provectus intends to pursue further investments and partnerships with high-quality ophthalmology providers in key urban centers across the region, consolidating expertise, expanding patient access and creating a regional leader in specialist eye care.
In parallel, Provectus will undertake a greenfield investment in a new state-of-the-art ophthalmology polyclinic in Zagreb, expected to open in Q2 2026, further strengthening the platform’s footprint and surgical capacity in Croatia.
Commenting on the transaction, Silvijo Radušić, Managing Director at Provectus, said:
“This investment marks the launch of our ophthalmology platform and the first transaction of PCP SEE Fund II. We see a clear opportunity to build the leading regional provider of specialist eye care in Southeast Europe. By partnering with outstanding medical professionals such as Dr. Balog and supporting further consolidation in a highly fragmented market, we aim to create a platform defined by clinical excellence, scale and long-term sustainability.”
Dr Slaven Balog, founder of Polyclinic dr Balog, added:
“We are proud of the reputation and clinical standards we have built at Polyclinic dr Balog over the years. Partnering with Provectus provides us with the strategic and financial support to further develop our services, invest in advanced technology, and continue delivering the highest level of care to our patients. We look forward to contributing to the creation of a strong regional ophthalmology platform.”
The SEE ophthalmology sector growth is underpinned by long-term structural healthcare trends, including growing demand for specialist eye care and improved access to advanced treatments. With this investment, Provectus positions itself as a first mover in building a regional healthcare leader in ophthalmology.
This transaction represents the first completed investment of PCP SEE Fund II and reinforces Provectus’ continued commitment to healthcare as a core investment sector in Southeast Europe.